These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 16439533)

  • 1. Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.
    Stone GW; Barzee S; Snarsky V; Kee K; Spina CA; Yu XF; Kornbluth RS
    J Virol; 2006 Feb; 80(4):1762-72. PubMed ID: 16439533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine.
    Kanagavelu SK; Snarsky V; Termini JM; Gupta S; Barzee S; Wright JA; Khan WN; Kornbluth RS; Stone GW
    Vaccine; 2012 Jan; 30(4):691-702. PubMed ID: 22146759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macaque multimeric soluble CD40 ligand and GITR ligand constructs are immunostimulatory molecules in vitro.
    Stone GW; Barzee S; Snarsky V; Spina CA; Lifson JD; Pillai VK; Amara RR; Villinger F; Kornbluth RS
    Clin Vaccine Immunol; 2006 Nov; 13(11):1223-30. PubMed ID: 16988005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination with a fusion protein that introduces HIV-1 gag antigen into a multitrimer CD40L construct results in enhanced CD8+ T cell responses and protection from viral challenge by vaccinia-gag.
    Gupta S; Termini JM; Raffa FN; Williams CA; Kornbluth RS; Stone GW
    J Virol; 2014 Feb; 88(3):1492-501. PubMed ID: 24227853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
    Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA
    Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trimeric HIV-1 gp140 fused with APRIL, BAFF, and CD40L on the mucosal gp140-specific antibody responses in mice.
    Liu J; Clayton K; Gao W; Li Y; Zealey C; Budylowski P; Schwartz J; Yue FY; Bie Y; Rini J; Ostrowski M
    Vaccine; 2020 Feb; 38(9):2149-2159. PubMed ID: 32014267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model.
    Gupta S; Termini JM; Rivas Y; Otero M; Raffa FN; Bhat V; Farooq A; Stone GW
    Vaccine; 2015 Sep; 33(38):4798-806. PubMed ID: 26241951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines.
    Ceglia V; Zurawski S; Montes M; Kroll M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
    Front Immunol; 2021; 12():786144. PubMed ID: 35095862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand.
    Wyzgol A; Müller N; Fick A; Munkel S; Grigoleit GU; Pfizenmaier K; Wajant H
    J Immunol; 2009 Aug; 183(3):1851-61. PubMed ID: 19596991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 adenoviral vector vaccines expressing multi-trimeric BAFF and 4-1BBL enhance T cell mediated anti-viral immunity.
    Kanagavelu S; Termini JM; Gupta S; Raffa FN; Fuller KA; Rivas Y; Philip S; Kornbluth RS; Stone GW
    PLoS One; 2014; 9(2):e90100. PubMed ID: 24587225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.
    Bower JF; Yang X; Sodroski J; Ross TM
    J Virol; 2004 May; 78(9):4710-9. PubMed ID: 15078953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
    Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
    J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model.
    Earl PL; Wyatt LS; Montefiori DC; Bilska M; Woodward R; Markham PD; Malley JD; Vogel TU; Allen TM; Watkins DI; Miller N; Moss B
    Virology; 2002 Mar; 294(2):270-81. PubMed ID: 12009868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative immunogenicity of human immunodeficiency virus particles and corresponding polypeptides in a DNA vaccine.
    Akahata W; Yang ZY; Nabel GJ
    J Virol; 2005 Jan; 79(1):626-31. PubMed ID: 15596858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice.
    Shephard E; Burgers WA; Van Harmelen JH; Monroe JE; Greenhalgh T; Williamson C; Williamson AL
    AIDS Res Hum Retroviruses; 2008 Feb; 24(2):207-17. PubMed ID: 18240963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques.
    Smith JM; Amara RR; McClure HM; Patel M; Sharma S; Yi H; Chennareddi L; Herndon JG; Butera ST; Heneine W; Ellenberger DL; Parekh B; Earl PL; Wyatt LS; Moss B; Robinson HL
    AIDS Res Hum Retroviruses; 2004 Jun; 20(6):654-65. PubMed ID: 15242543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens.
    Gómez CE; Nájera JL; Sánchez R; Jiménez V; Esteban M
    Vaccine; 2009 May; 27(24):3165-74. PubMed ID: 19446187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of a soluble recombinant trimeric form of bovine CD40L and its potential use as a vaccine adjuvant in cows.
    Pujol J; Bouillenne F; Farnir F; Dufrasne I; Mainil J; Galleni M; Lekeux P; Bureau F; Fiévez L
    Vet Immunol Immunopathol; 2015 Nov; 168(1-2):1-13. PubMed ID: 26553560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells.
    Melchers M; Matthews K; de Vries RP; Eggink D; van Montfort T; Bontjer I; van de Sandt C; David K; Berkhout B; Moore JP; Sanders RW
    Retrovirology; 2011 Jun; 8():48. PubMed ID: 21689404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.